A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells

Gene Therapy

Volumn 4, Issue 10, 1997, Pages 1013-1022

  Cheng, L ^a,d   Du, C ^a   Murray, D ^b   Tong, X ^a   Zhang, Y A ^c   Chen, B P ^a   Hawley, R G ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d Stem Cell Molecular Biology   (United States)

Author keywords

Gene expression; Gene therapy; Gene transfer; GFP; Hematopoietic stem cells; Retroviral vectors

Indexed keywords

CD34 ANTIGEN; GREEN FLUORESCENT PROTEIN; VIRUS VECTOR;

ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC STABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; RETROVIRUS; TARGET CELL;

UNIDENTIFIED RETROVIRUS;

EID: 0030775308     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300507     Document Type: Article

References (46)

1. Dunbar CE. Gene-transfer to hematopoietic stem cells: implications for gene therapy of human diseases. Ann Rev Med 1996; 47: 11-20.
2. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Meth Enzymol 1993; 217: 581-599.
3. Mulligan RG. The basic science of gene therapy. Science 1993; 260: 926-932.
4. Hawley RG. Therapeutic potential of retroviral vectors. Transfus Sci 1996; 17: 7-14.
5. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
6. Ross G et al. Gene therapy in the United States: a five year status report. Hum Gene Ther 1996; 7: 1781-1790.
7. Stewart AK, Dube ID, Hawley RG. Gene marking and the biology of hematopoietic cell transfer in human clinical trials. In- Fairbairn LJ, Testa N (eds). Blood Cell Biochemistry: Hematopoiesis and Gene Therapy. New York: Plenum, 1997 (in press).
8. Hawley RG et al. Thrombopoietic potential and serial repopulating ability of munne hematopoietic stem cells constitutively expressing interleukin-11. Proc Natl Acad Sci USA 1996; 93: 10297-10302.
9. Hock RA, Miller AD, Osborne WR. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 1989; 74: 876-881.
10. Plavec I et al. High transdominant Rev10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells, implication for HIV gene therapy of AIDS. Gene Therapy 1997; 4: 128-137
11. Challita P-M, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994; 91: 2567-2571.
12. Lu M et al. Retrovirus-mediated gene expression in hematopoictic cells correlates inversely with growth factor stimulation. Hum Gene Ther 1996; 7: 2263-2271.
13. Hawley RG, Lieu FHL, Fong AZC, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
14. Chalfie M et al. Green fluorescent protein as a marker for gene expression. Science 1994; 283: 802-805.
15. Cubbit AB et al. Understanding, improving and using green fluorescent ptoteins. Trends Biol Sci 1995; 20: 448-455.
16. Youvan DC, Larrick JW (eds). Gene 1996; 173: 1-117.
17. Cheng L, Fu J, Tsukamoto A, Hawley RG. Use of green fluorescent protein variants to monitor gene transfer and expression in mammalian cells. Nature Biotech 1996; 14: 606-609.
18. Levy JP, Muldoon RR, Zolotukhin S, Link CJ Jr. Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene in human tumor cells. Nature Biotech 1996; 14: 610-614.
19. Zolotukhin S, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high level expression for mammalian cells. J Virol 1996; 70: 4646-4654.
20. Cormack BP, Valdivia RH, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 1996; 173: 33-38.
21. Yang T-T, Cheng L, Kain SR. Optimized codon usage and chromophore mutations provide enhanced sensitivity with the green fluorescent protein. Nucleic Acids Res 1996; 24: 4592-4593.
22. Finer MF et al. kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83: 43-50.
23. Conneally E et al. Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retrovirus-mediated gene transfer. Blood 1996; 87: 456-464.
24. Correll PH, Colilla S, Karlsson S. Retroviral vector design for long-term expression in murine hematopoietic cells in vivo. Blood 1994; 84: 1812-1822.
25. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
26. Ghattas IR, Sanes JR, Major JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848-5859.
27. Hawley RG et al. Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann NY Acad Sci 1996; 795: 341-345.
28. Rigg RJ et al. A novel human amphotropic packaging cell line: high titer, complement-resistance and improved safety. Virology 1996; 218: 290-295.
29. Kitamura T et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3 or erythropoietin. J Cell Physiol 1989; 140: 323-334.
30. Ploemacher RE, van der Sluijs JP, Voerman JSA, Brons NHC. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood 1989; 74: 2755-2763.
31. - subpopulation from mobilized peripheral blood. Blood 1995; 85: 368-378.
32. Phillips K et al. Cell-surface markers for assessing gene transfer into human hematopoietic cells. Nature Med 1996; 2: 1154-1156.
33. Nolan GP, Fiering S, Nicolas J-F, Herzenberg LA. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc Natl Acad Sci USA 1988; 85: 2603-2607.
34. Ikawa M et al. Green fluorescent protein as a marker in transgenic mice. Develop Growth Diff 1995; 37: 455-459.
35. Ikawa M et al. A rapid and non-invasive selection of transgenic embryos before implantation using green fluorescent protein (GFP). FEBS Lett 1995; 375: 125-128.
36. Bartlett RJ et al. Long-term expression of a fluorescent reporter gene via direct injection of plasmid vectors into mouse skeletal muscle: comparison of human creatine kinase and CMV promoter expression levels in vivo. Cell Transplant 1996; 5: 411-419.
37. Peel A et al. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 1997; 4: 16-24.
38. Larochelle A et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nature Med 1996; 2: 1329-1337.
39. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 459-467.
40. Proudfoot NJ. Transcriptional interference and termination between duplicated α-globin gene constructs suggests a novel mechanism for gene regulation. Nature 1986; 322: 562-565.
41. Zitvogel L et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 1994; 5: 1493-1506.
42. Treisman J et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 1995; 85: 139-145.
43. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
44. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
45. Burns JC et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
46. Kotani H et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28